Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

OCE Project Confirm Takes Shape: Ongoing Confirmatory Trials At Time Of AA Offers Average Two-Year Faster Approval Conversion

June 16, 2022

FDA’s Vaccines Advisory Committee Unanimously Recommends Authorization Of Pfizer, Moderna COVID Vaccines In Young Children; Agency Will Turn Attention To Strain Composition For 2022/2023

June 16, 2022

Prevision Policy Clips | 340B Part B Payment Cuts “Unlawful,” Supreme Court Rules

June 16, 2022

RCT-DUPLICATE Project Will Guide Future RWE Guidances; Four-Year Project In Claims Data Identifies Issues To Watch

June 15, 2022

FDA Inspections Update: Domestic Pre-Approval Inspection Backlog Has Been Cleared; China Remains “Difficult” For Resuming Normal Work

June 15, 2022

FDASLA Moves Forward In Senate, But GOP Sponsor Becomes “Burr” To Smooth Progress; User Fee Bill Moves Closer To House Version, But Tone Diverges Sharply

June 15, 2022

Acadia’s Nuplazid For Alzheimer’s Psychosis: FDA Panel Review Will Serve As Long-Shot Appeal; Agency “Does Not Agee” With Arguments For New Use

June 15, 2022

Prevision Policy Clips | Regenerative Medicine “Consensus Standards” Program Modeled On Devices Proposed By CBER

June 15, 2022

Accelerated Approval Reforms: FDA’s Califf Sees Evidence Generation—Not Speed To Market—As Correct Focus For Legislation

June 14, 2022

Senate User Fee Bill Would Codify FDA Certification Program For Canadian Rx Imports: Stronger Legal Basis But Also Likely Further Delay In Implementation

June 14, 2022

Prevision Policy Clips | Senate FDA User Fee Bill Adds Provision Codifying Canadian Import Certification Process

June 14, 2022

CBER Advanced Technologies Team Getting “High Interest” From Industry On Platform Technologies; Center Coordinating With CDER On Advanced Manufacturing Evaluation Framework

June 13, 2022

Prevision Policy Clips | FDA Commissioner Califf Set To Testify At Senate HELP COVID Response Hearing June 16

June 13, 2022

Bluebird Beti-Cel Takes FDA Back To Gene Therapy Replacements For Current Treatments; Thalassemia Vote Means Bluebird Has Two BLAs To Finish Over Summer

June 13, 2022

Quantifying The Slowdown In Gene/Cell Therapy INDs During COVID: Gene Therapy Submissions Plateau In 2021, Dropoff Seen In Cell Therapy Submissions

June 10, 2022

Prevision Policy Clips | Gene Therapy Regulatory Environment Gets Nice Boost From Bluebird Bio Unanimous Eli-Cel Vote

June 10, 2022

Bluebird Bio’s Eli-Cel: FDA Asks Sponsor For Analysis On Unmatched Donor Sub-Group; That Impresses Advisory Committee, Earns Unanimous OK

June 10, 2022

FTC Study Of PBMs Digs Deep On Specific Drug Classes: Broad Scope But Impact Depends On Political Climate When Report Is Done; Prior Authorization Policy May Be Sleeper Issue

June 9, 2022

Prevision Policy Clips | “FDA22” User Fee Reauthorization Passes House

June 9, 2022

Novavax COVID-19 Vaccine Breezes Through Committee Thanks To FDA Case For Unmet Need; Manufacturing Review Is Final Obstacle To EUA

June 8, 2022

Prevision Policy Clips | FTC Launches Broad Study Of PBM Practices, Asking Top Six PBMS About Seven Different Topics

June 8, 2022

Bluebird’s Beti-Cel Thalassemia Gene Therapy: FDA Asking Committee How To View “Worrisome” Long-Term Safety Concerns In Face Of Clinical Benefit

June 8, 2022

Bluebird’s Eli-Cel For CALD: Complex Review Includes Cancer Risk Among Safety Concerns Mixed With Efficacy Interpretability Challenges Posed By FDA

June 7, 2022

CDER Workplace “Culture” Is Focus Of Retention Efforts After COVID; Re-Vamped “Equal Voice” Process Is One Step

June 7, 2022

Prevision Policy Clips | House Expected To Pass FDA User Fee Reauthorization Bill Today

June 7, 2022
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2022 Prevision Policy. All Rights Reserved. Privacy Policy